CanVECTOR Network

The Canadian Venous Thromboembolism Research Network is a pan-Canadian, patient-oriented research network dedicated to VTE.

[Tobias Tritschler @TritschlerMD]

A long journey has come to an end. This article brings together what we set out to do, but it also captures the challenges and precious lessons we learned along the way.

https://t.co/Ep095z8B3C

[Marc Carrier @MarcCarrier1]

What a fantastic evening celebrating the 25th anniversary of the Adult Thrombosis Fellowship Program at the University of Ottawa during the #ISTH2026 meeting in Paris!

It was wonderful to reconnect with so many former fellows who trained in Ottawa. Thank you to everyone who joined us to celebrate this incredible milestone and to all our fellows.

Looking forward to the next 25 years!

@isth @ThrombosisCan @canvector

[ISTH @isth]

Even though #ISTH2026 is in full swing, we’re already looking forward to #ISTH2027 in Vancouver! Stop by the ISTH booth TODAY to get some special swag.

“Whale” see you in Vancouver!! 🫍

[Marc Carrier @MarcCarrier1]

🎉 Congratulations to Dr. @RodgerMarc and the entire team on their @isth oral presentation! 👏

🤰 An unlikely LEFt score + negative D-dimer safely excluded suspected #DVT in pregnancy without ultrasound.

📊 No VTE events occurred in this low-risk group, while a likely LEFt score identified patients at high risk (≈28% VTE), supporting prompt imaging and close follow-up.

An important step toward safer, evidence-based care for pregnant patients. 👏🔬
#ISTH2026

[Patricia Liaw @PatriciaLiaw]

Congratulations to ISTH 2026 Esteemed Career Award Recipients! Drs. Susan Kahn 🇨🇦, Philip Wells 🇨🇦, Michael Lafan, Paolo Prandoni, Maria das Gravas Carvalho. Their accomplishments are exemplary models of research, clinical practice and mentoring excellence. 🥂👏

[INVENT-VTE @INVENT_VTE]

Join us TODAY for the Dragons' Den Competition at #ISTH2026!

Watch 4 investigators pitch their thrombosis studies for a $35,000 CAD prize & network endorsement!

🗳️ Vote for your fav pitch!

🗓️ Today at 12:30 PM 📍 Room S04

https://t.co/cZYC5S1S6B

#VTE #Thrombosis #Research

[Marc Carrier @MarcCarrier1]

🎉 Congratulations to Dr. @sudeeppappur and the entire #EPCATIII team!

A true highlight of #ISTH2026 in Paris: a Late-Breaking Abstract with simultaneous publication in @NEJM.

Practice-changing results showing that aspirin alone after total hip or knee arthroplasty was noninferior to an initial 5-day course of rivaroxaban followed by aspirin for preventing symptomatic VTE, with no clinically meaningful difference in bleeding.

https://t.co/RDvM6MQ2xZ
@ThrombosisCan @canvector @isth

[Professor Susan R Kahn @SusanRKahn1]

Congrats to @sudeeppappur and the EPCAT-3 team @canvector: *happening now* simultaneous @NEJM publication and presentation at @ISTH2026: Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty | New England Journal of Medicine https://t.co/r9TT4WPjyL

[Marc Carrier @MarcCarrier1]

🎉🩸 We're celebrating 25 years of the Adult Thrombosis Medicine Fellowship at the University of Ottawa!

🌍 Over 90 thrombosis specialists trained from 🇨🇦🇫🇷🇨🇭🇺🇾🇪🇹🇸🇦🇰🇼🇴🇲🇦🇺🇧🇷🇮🇹🇬🇧🇲🇽 and many more.

🗼 During #ISTH2026 in Paris, we'll be hosting a 25th Anniversary Reunion!

🎓 Were you an Ottawa Thrombosis Fellow?
✈️ Will you be at ISTH?
🤝 We'd love to reconnect!
📧 Please contact our Program Director, Dr. @DellucAurelien, if you'd like to join us.

[CanVECTOR Network @canvector]

Join us for the final 2025–26 National #Thrombosis seminar: "Precision in DOAC reversal — a trainee-led UK network."

June 8, 12:00 ET | Featuring Dr Richard Buka !

Register to attend: https://t.co/4FyU19hC0U

#Anticoagulation #VTE #Research

[INVENT-VTE @INVENT_VTE]

The debate over DOAC selection just got clearer. 🔍

The #COBRRA trial provides a definitive head-to-head look at bleeding risks in #VTE. Tomorrow, we explore the findings!

Join the deep dive with @LanaCastellucci

Register to attend🔗 https://t.co/HdiDXD52Z8

#Research

[ISTH @isth]

Susan Kahn is a leading voice in venous thrombosis & its long-term complications. Her work has helped shape patient care and clinical practice globally. Now honored with the 2026 ISTH Esteemed Career Award, she reflects on her career: https://t.co/hkveUMn7wd

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary: https://t.co/tvPYrBCWj8

[IRSC @IRSC_CIHR]

Dans le cadre d’une étude menée par la Dre Lana Castellucci, deux types d’anticoagulants souvent utilisés pour traiter la thromboembolie veineuse ont été comparés. L’un de ces médicaments a pu diminuer de plus de 50 % les cas d’hémorragie.

https://t.co/sHBPvlApo6

[CIHR @CIHR_IRSC]

A study led by Dr. Lana Castellucci compared two types of anticoagulants commonly used to treat venous thromboembolism and showed that one of the medications reduced bleeding by more than 50%.

Learn more: https://t.co/IGN4Rev8Hr
#BloodClotAwarenessMonth

[CTV Ottawa @ctvottawa]

Groundbreaking research at The Ottawa Hospital https://t.co/LYdc1ZUhZt

[Nicola Potere @NicolaPotereMD]

🐍 COBRRA trial finds ↓ clinically relevant bleeding with apixaban vs. rivaroxaban during the first 3 months of treatment for acute VTE (RR 0.46, 95% CI 0.33–0.65)🩸

@uOttawaMed @OttawaHospital @CIHR_IRSC @INVENT_VTE

[CTV Ottawa @ctvottawa]

Ottawa Hospital research finds ‘clear winner’ for safer blood clot treatment https://t.co/RDTNvp7Mwt

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.

Full COBRRA trial results: https://t.co/tvPYrBCWj8

[Marc Carrier @MarcCarrier1]

Excited to share this fantastic new tool from @ASH_hematology

https://t.co/px2XkLlTBD

TrialMap is the perfect resource for early-career clinician investigators. Guiding you from trial concept 💡 to practice-changing results 📄.

A must-bookmark if launching a clinical trial!